Author's response to reviews

Title: Final results of a phase I/II pilot study of capecitabine with or without vinorelbine after sequential dose-dense epirubicin and paclitaxel in high-risk early breast cancer

Authors:

Volkmar Müller (vmueller@uke.de)
Thomssen Christoph (christoph.thomssen@medizin.uni-halle.de)
Marcus Schmidt (marcus.schmidt@frauen.klinik.uni-mainz.de)
Manfred Glados (praxis.dr.glados@t-online.de)
Christian Jackisch (Christian.Jackisch@klinikum-offenbach.de)
Volker Heilmann (v.heilmann@praxis-dr-heilmann.de)
Axel Hinke (axel.hinke@wisp.de)
Antje Lehnert (antje.lehnert@gmx.de)
Henryk Borowicz (h.borowicz@frauenarzt-borowicz.de)
Volker Moebus (volker.moebus@klinikumfrankfurt.de)

Version: 4 Date: 12 August 2010

Author's response to reviews:

Author note:
All the changes addressed below were made in the revised manuscript.

-----------------------------

Editorisal comments:

Major revisions (we require the author to make these changes)
Authors' contributions: Please indicate that all authors read and approved the final manuscript.
Minor revisions (we can make these changes for you, although it will speed up publication of your manuscript if you do them while making the major changes above)
Introduction: please rename this section 'Background'
Patients and methods: please rename this section 'Methods'
Highlighting/tracking: Please remove all highlighting and tracking from the manuscript.
Figures: Please ensure all mention of figures is consistent (it should be Figure or Fig but not a mixture of both)
References: the reference list should contain up to 30 authors' names for each citation. The term 'et al.' should not be used if there are fewer than 30 authors.
Typography: Please take this opportunity to check your manuscript for any typographical errors and to make any final corrections or revisions. This is the final proofing stage for your manuscript, and you will not be able to make any changes after acceptance.